PSMA 표적 방사성 색종 약물 복합체 시장 분석 및 예측(-2035년) : 유형, 제품, 기술, 용도, 프로세스, 전개, 최종 사용자, 기능

The global Targeted PSMA Radionuclide Drug Conjugates Market is projected to grow from $2.1 billion in 2025 to $4.3 billion by 2035, at a compound annual growth rate (CAGR) of 7.2%. The Targeted PSMA Radionuclide Drug Conjugates Market is characterized by a moderately consolidated structure, with the top three segments comprising approximately 70% of the market share. The leading segments include prostate cancer treatment, which holds around 45%, followed by diagnostic applications at 25%. The market is primarily driven by the increasing prevalence of prostate cancer and advancements in targeted therapy. The volume insights indicate a growing number of installations and treatments, particularly in North America and Europe, where healthcare infrastructure is more developed.

Based on Application, the Targeted PSMA Radionuclide Drug Conjugates Market is divided into Prostate Cancer Treatment, Metastatic Cancer Detection, Theranostics, and Others. Among these, the Prostate Cancer Treatment segment accounted for the largest market share in 2025. This dominance is attributed to the increasing prevalence of prostate cancer globally and the rising adoption of PSMA-targeted radionuclide therapies as an effective treatment approach for advanced and metastatic prostate cancer. These therapies enable selective targeting of PSMA-expressing cancer cells, allowing precise radiation delivery while reducing damage to surrounding healthy tissues. Growing clinical evidence supporting improved patient outcomes, increasing regulatory approvals, and rising investments in radiopharmaceutical development are further driving the adoption of targeted PSMA therapies in prostate cancer management.

Based on Functionality, the Targeted PSMA Radionuclide Drug Conjugates Market is divided into Targeted Delivery, Radiation Therapy, Imaging, and Others. Among these, the Theranostic-focused Radiation Therapy functionality segment is projected to witness the fastest growth during the forecast period. The rapid expansion is driven by the increasing demand for personalized cancer treatment approaches that combine precise diagnosis with targeted therapeutic intervention. PSMA radionuclide drug conjugates enable real-time tumor visualization followed by targeted radiation treatment, improving treatment selection and monitoring. Advancements in radionuclide technology, growing availability of alpha and beta emitters, and increasing adoption of precision oncology approaches are expected to accelerate the growth of radiation therapy applications within the targeted PSMA radionuclide drug conjugates market.

Geographical Overview

North America accounted for the largest share of the Targeted PSMA Radionuclide Drug Conjugates Market in 2025 due to its advanced oncology infrastructure, strong adoption of precision medicine, and extensive availability of nuclear medicine facilities. The region benefits from a high prevalence of prostate cancer, significant investments in radiopharmaceutical research, and the presence of leading biotechnology and pharmaceutical companies developing targeted radionuclide therapies. Favorable reimbursement frameworks, increasing clinical trial activity, and early adoption of innovative cancer treatments further support market expansion. Continuous advancements in molecular imaging and theranostic applications continue to reinforce North America's leadership in this market.

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to rising prostate cancer awareness, improving nuclear medicine infrastructure, and increasing investments in advanced oncology care. Countries including China, Japan, South Korea, and Australia are expanding access to precision diagnostics and targeted cancer therapies through government healthcare initiatives and private sector investments. Growing research collaborations, improving regulatory pathways, and increasing availability of PET imaging facilities are accelerating regional adoption. Expanding healthcare expenditure and the growing focus on personalized cancer treatment are expected to drive significant market growth across Asia-Pacific.

Key Trends and Drivers

Rising Incidence of Prostate Cancer and Demand for Targeted Therapies:

The increasing global prevalence of prostate cancer is a major driver for the Targeted PSMA Radionuclide Drug Conjugates Market. Growing demand for highly targeted treatment approaches that selectively destroy cancer cells while minimizing damage to healthy tissues is encouraging the adoption of PSMA-targeted radionuclide therapies. These therapies offer improved treatment precision and enhanced clinical outcomes for patients with advanced or metastatic prostate cancer. Increasing awareness, expanding diagnostic capabilities, and ongoing clinical research into targeted radiopharmaceuticals are further supporting market growth as healthcare providers seek more effective oncology treatment options.

Expansion of Theranostic Approaches in Oncology:

A key trend in the Targeted PSMA Radionuclide Drug Conjugates Market is the growing adoption of theranostics, which combines diagnostic imaging and targeted therapy using the same molecular target. Healthcare providers are increasingly utilizing PSMA-targeted agents for both disease detection and personalized treatment planning, improving therapeutic precision and patient outcomes. Advances in radiopharmaceutical development, companion diagnostics, and nuclear medicine technologies are accelerating this integrated treatment approach. The continued evolution of precision oncology is positioning theranostics as a transformative trend within prostate cancer diagnosis and treatment.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Deployment
• 2.8 Key Market Highlights by Functionality

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Small Molecule Conjugates
  • 4.1.2 Antibody Conjugates
  • 4.1.3 Peptide Conjugates
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Therapeutic Agents
  • 4.2.2 Diagnostic Agents
  • 4.2.3 Combination Agents
  • 4.2.4 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Radioisotope Labeling
  • 4.3.2 Linker Technology
  • 4.3.3 Targeting Ligands
  • 4.3.4 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Prostate Cancer Treatment
  • 4.4.2 Metastatic Cancer Detection
  • 4.4.3 Theranostics
  • 4.4.4 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Cancer Research Institutes
  • 4.5.3 Specialty Clinics
  • 4.5.4 Diagnostic Laboratories
  • 4.5.5 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Synthesis
  • 4.6.2 Purification
  • 4.6.3 Quality Control
  • 4.6.4 Others
• 4.7 Market Size & Forecast by Deployment (2020-2035)
  • 4.7.1 In-House Manufacturing
  • 4.7.2 Contract Manufacturing
  • 4.7.3 Others
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Targeted Delivery
  • 4.8.2 Radiation Therapy
  • 4.8.3 Imaging
  • 4.8.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Deployment
    • 5.2.1.8 Functionality
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Deployment
    • 5.2.2.8 Functionality
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Deployment
    • 5.2.3.8 Functionality
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Deployment
    • 5.3.1.8 Functionality
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Deployment
    • 5.3.2.8 Functionality
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Deployment
    • 5.3.3.8 Functionality
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Deployment
    • 5.4.1.8 Functionality
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Deployment
    • 5.4.2.8 Functionality
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Deployment
    • 5.4.3.8 Functionality
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Deployment
    • 5.4.4.8 Functionality
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Deployment
    • 5.4.5.8 Functionality
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Deployment
    • 5.4.6.8 Functionality
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Deployment
    • 5.4.7.8 Functionality
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Deployment
    • 5.5.1.8 Functionality
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Deployment
    • 5.5.2.8 Functionality
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Deployment
    • 5.5.3.8 Functionality
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Deployment
    • 5.5.4.8 Functionality
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Deployment
    • 5.5.5.8 Functionality
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Deployment
    • 5.5.6.8 Functionality
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Deployment
    • 5.6.1.8 Functionality
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Deployment
    • 5.6.2.8 Functionality
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Deployment
    • 5.6.3.8 Functionality
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Deployment
    • 5.6.4.8 Functionality
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Deployment
    • 5.6.5.8 Functionality

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Novartis
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Bayer
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Telix Pharmaceuticals
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Curium Pharma
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Fusion Pharmaceuticals
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Progenics Pharmaceuticals
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 ITM Isotope Technologies Munich
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Endocyte
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Lantheus Holdings
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Advanced Accelerator Applications
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Nordion
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Sofie Biosciences
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 RadioMedix
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Actinium Pharmaceuticals
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Clarity Pharmaceuticals
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Theragnostics
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Alpha Tau Medical
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 NorthStar Medical Radioisotopes
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Isotopia Molecular Imaging
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Artios Pharma
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us